Cargando…
Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease
Drainage of interstitial fluid from the brain occurs via the intramural periarterial drainage (IPAD) pathways along the basement membranes of cerebral capillaries and arteries against the direction of blood flow into the brain. The cerebrovascular smooth muscle cells (SMCs) provide the motive force...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560129/ https://www.ncbi.nlm.nih.gov/pubmed/32971843 http://dx.doi.org/10.3390/ph13090261 |
_version_ | 1783595018048503808 |
---|---|
author | Frost, Miles Keable, Abby Baseley, Dan Sealy, Amber Andreea Zbarcea, Diana Gatherer, Maureen Yuen, Ho Ming Sharp, Matt MacGregor Weller, Roy O. Attems, Johannes Smith, Colin Chiarot, Paul R. Carare, Roxana O. |
author_facet | Frost, Miles Keable, Abby Baseley, Dan Sealy, Amber Andreea Zbarcea, Diana Gatherer, Maureen Yuen, Ho Ming Sharp, Matt MacGregor Weller, Roy O. Attems, Johannes Smith, Colin Chiarot, Paul R. Carare, Roxana O. |
author_sort | Frost, Miles |
collection | PubMed |
description | Drainage of interstitial fluid from the brain occurs via the intramural periarterial drainage (IPAD) pathways along the basement membranes of cerebral capillaries and arteries against the direction of blood flow into the brain. The cerebrovascular smooth muscle cells (SMCs) provide the motive force for driving IPAD, and their decrease in function may explain the deposition of amyloid-beta as cerebral amyloid angiopathy (CAA), a key feature of Alzheimer’s disease. The α-adrenoceptor subtype α(1A) is abundant in the brain, but its distribution in the cerebral vessels is unclear. We analysed cultured human cerebrovascular SMCs and young, old and CAA human brains for (a) the presence of α(1A) receptor and (b) the distribution of the α(1A) receptor within the cerebral vessels. The α(1A) receptor was present on the wall of cerebrovascular SMCs. No significant changes were observed in the vascular expression of the α(1A)-adrenergic receptor in young, old and CAA cases. The pattern of vascular staining appeared less punctate and more diffuse with ageing and CAA. Our results show that the α(1A)-adrenergic receptor is preserved in cerebral vessels with ageing and in CAA and is expressed on cerebrovascular smooth muscle cells, suggesting that vascular adrenergic receptors may hold potential for therapeutic targeting of IPAD. |
format | Online Article Text |
id | pubmed-7560129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75601292020-10-22 Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease Frost, Miles Keable, Abby Baseley, Dan Sealy, Amber Andreea Zbarcea, Diana Gatherer, Maureen Yuen, Ho Ming Sharp, Matt MacGregor Weller, Roy O. Attems, Johannes Smith, Colin Chiarot, Paul R. Carare, Roxana O. Pharmaceuticals (Basel) Article Drainage of interstitial fluid from the brain occurs via the intramural periarterial drainage (IPAD) pathways along the basement membranes of cerebral capillaries and arteries against the direction of blood flow into the brain. The cerebrovascular smooth muscle cells (SMCs) provide the motive force for driving IPAD, and their decrease in function may explain the deposition of amyloid-beta as cerebral amyloid angiopathy (CAA), a key feature of Alzheimer’s disease. The α-adrenoceptor subtype α(1A) is abundant in the brain, but its distribution in the cerebral vessels is unclear. We analysed cultured human cerebrovascular SMCs and young, old and CAA human brains for (a) the presence of α(1A) receptor and (b) the distribution of the α(1A) receptor within the cerebral vessels. The α(1A) receptor was present on the wall of cerebrovascular SMCs. No significant changes were observed in the vascular expression of the α(1A)-adrenergic receptor in young, old and CAA cases. The pattern of vascular staining appeared less punctate and more diffuse with ageing and CAA. Our results show that the α(1A)-adrenergic receptor is preserved in cerebral vessels with ageing and in CAA and is expressed on cerebrovascular smooth muscle cells, suggesting that vascular adrenergic receptors may hold potential for therapeutic targeting of IPAD. MDPI 2020-09-22 /pmc/articles/PMC7560129/ /pubmed/32971843 http://dx.doi.org/10.3390/ph13090261 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Frost, Miles Keable, Abby Baseley, Dan Sealy, Amber Andreea Zbarcea, Diana Gatherer, Maureen Yuen, Ho Ming Sharp, Matt MacGregor Weller, Roy O. Attems, Johannes Smith, Colin Chiarot, Paul R. Carare, Roxana O. Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease |
title | Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease |
title_full | Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease |
title_fullStr | Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease |
title_full_unstemmed | Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease |
title_short | Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease |
title_sort | vascular α1a adrenergic receptors as a potential therapeutic target for ipad in alzheimer’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560129/ https://www.ncbi.nlm.nih.gov/pubmed/32971843 http://dx.doi.org/10.3390/ph13090261 |
work_keys_str_mv | AT frostmiles vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT keableabby vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT baseleydan vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT sealyamber vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT andreeazbarceadiana vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT gatherermaureen vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT yuenhoming vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT sharpmattmacgregor vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT wellerroyo vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT attemsjohannes vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT smithcolin vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT chiarotpaulr vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease AT carareroxanao vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease |